In an unexpected development, Gilead Sciences (GILD) disclosed that a generic version of its Truvada pill for preventing HIV will be sold by Teva Pharmaceuticals (TEVA) starting in September 2020, roughly a year earlier than had been expected.

Nonetheless, the news did little to assuage AIDS activists, who have been clamoring for a lower-cost version of the drug for the past few years, underscoring ongoing controversy over the cost of prescription medicines. Activists have complained that the price Gilead charges for its medicine has been a barrier to wider use and consequently thwarted efforts to eradicate the virus.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy